Talphera, Inc. (TLPH)

♥ 419 Thanks from members

Talphera, Inc. exhibits a speculative profile characterized by advancing clinical trials for its nafamostat NEPHRO CRRT study and conditional financing tranches, balanced against auditor going-concern warnings, substantial shareholder dilution, and micro-cap volatility.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Superior Group of Companies, Inc. (SGC)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

Entity & Market Metadata

Sector: Healthcare Industry: Biotechnology Founder: Dr. David Eldon Smith Leadership: Pamela Palmer (Co-Founder & CMO) Leadership: Nigel Standing (CEO) Holder: FMR LLC Holder: BlackRock, Inc. Subsys APF530 Nuvela #TLPH #Talphera Inc #Biotech Stock #Acute Care Therapeutics #NASDAQ TLPH